That’s the subtitle of a paper by Vreman et al. (2020). The authors take a look at all remedies permitted by FDA and EMA that had been subsequently reviewed by HTA our bodies in each jurisdictions between 1995 and 2018. The authors used ICER because the US HTA physique; European HTA our bodies included IQWiG (Germany), NICE (UK), ZIN (Netherlands), and EUnetHTA. From these studies the authors categorized any uncertainties talked about into six classes:
- Security: small pattern dimension, causality of adversarial occasions uninterpretable, long-term security
- Trial validity: Choice bias, efficiency bias, detection bias, attrition bias, reporting bias
- Inhabitants: Inhabitants doesn’t match apply, subgroups not adequately studied/reported
- Intervention: Unreliable or lacking data on interactions with different remedy, unreliable or lacking data on monotherapy or mixture routine, unreliable or lacking data on applicable therapy period
- Comparative results: Unreliable or lacking data on results in opposition to related comparators, unreliable oblique comparisons, unreliable or lacking data on applicable therapy line
- Outcomes: Unreliable or lacking data on long-term results, related outcomes not measured or reported
Utilizing this strategy, the authors evaluated 33 medication, protecting 34 indications. The authors discovered that 7.4 uncertainties (SD 3.8) had been raised per drug per establishment, with HTA our bodies extra more likely to elevate uncertainties in comparison with regulators. What did the authors discover:
Issues of safety—comparable to these associated to pattern dimension or uncertainties in causality—had been raised by regulators for nearly all medication assessed (94% for the FDA and 85% for the EMA). HTA our bodies raised issues of safety for under 59% (ICER) and 53% (AGGR-EUR) of medication…
HTA our bodies raised uncertainties associated to results in opposition to related comparators for nearly all medication (100% in the USA and 88% in Europe), whereas this class was hardly addressed by the FDA (12%) and solely barely extra by the EMA (32%).
One can see the breakdown by class visually within the graph under.
Fascinating all through. You may learn the complete paper right here.